Timothy A Mckinsey

List of Publications by Year
in descending order

84 papers	5,599 citations	81900 39 h-index	82547 72 g-index
85 all docs	85 docs citations	85 times ranked	6387 citing authors

#	Article	IF	Citations
1	Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy. Cell, 2002, 110, 479-488.	28.9	878
2	Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development. Molecular and Cellular Biology, 2004, 24, 8467-8476.	2.3	548
3	Dose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors. Journal of Biological Chemistry, 2003, 278, 28930-28937.	3.4	241
4	Therapeutic Potential for HDAC Inhibitors in the Heart. Annual Review of Pharmacology and Toxicology, 2012, 52, 303-319.	9.4	215
5	BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Science Translational Medicine, 2017, 9, .	12.4	203
6	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2013, 63, 175-179.	1.9	154
7	Selective Class I Histone Deacetylase Inhibition Suppresses Hypoxia-Induced Cardiopulmonary Remodeling Through an Antiproliferative Mechanism. Circulation Research, 2012, 110, 739-748.	4.5	152
8	Regulation of Cardiac Stress Signaling by Protein Kinase D1. Molecular and Cellular Biology, 2006, 26, 3875-3888.	2.3	147
9	Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. Journal of Molecular and Cellular Cardiology, 2014, 67, 112-125.	1.9	146
10	Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes. Annals of the Rheumatic Diseases, 2017, 76, 277-285.	0.9	118
11	Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Science Translational Medicine, 2018, 10, .	12.4	114
12	Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9806-9811.	7.1	107
13	Derepression of pathological cardiac genes by members of the CaM kinase superfamily. Cardiovascular Research, 2007, 73, 667-677.	3.8	105
14	Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation. Circulation Research, 2019, 125, 662-677.	4.5	105
15	Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. Journal of Molecular and Cellular Cardiology, 2011, 51, 41-50.	1.9	101
16	A transcriptional switch governs fibroblast activation in heart disease. Nature, 2021, 595, 438-443.	27.8	100
17	HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H252-H258.	3.2	97
18	Tubulin hyperacetylation is adaptive in cardiac proteotoxicity by promoting autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5178-86.	7.1	92

#	Article	IF	Citations
19	Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1631-1636.	7.1	91
20	Isoform-selective HDAC inhibitors: Closing in on translational medicine for the heart. Journal of Molecular and Cellular Cardiology, 2011, 51, 491-496.	1.9	88
21	Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors. Molecular Medicine, 2011, 17, 434-441.	4.4	85
22	Epigenetics in Cardiac Fibrosis. JACC Basic To Translational Science, 2018, 3, 704-715.	4.1	75
23	HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. Science Translational Medicine, 2020, 12, .	12.4	75
24	Targeting cardiac fibroblasts to treat fibrosis of the heart: Focus on HDACs. Journal of Molecular and Cellular Cardiology, 2014, 70, 100-107.	1.9	72
25	HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling. Circulation, 2021, 143, 1874-1890.	1.6	71
26	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Reports, 2016, 16, 1366-1378.	6.4	70
27	Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression. Annals of the Rheumatic Diseases, 2016, 75, 430-438.	0.9	68
28	Metabolomics assessment reveals oxidative stress and altered energy production in the heart after ischemic acute kidney injury in mice. Kidney International, 2019, 95, 590-610.	5.2	61
29	Physiological Biomimetic Culture System for Pig and Human Heart Slices. Circulation Research, 2019, 125, 628-642.	4.5	60
30	Nuclear PTEN functions as an essential regulator of SRF-dependent transcription to control smooth muscle differentiation. Nature Communications, 2016, 7, 10830.	12.8	53
31	Therapeutic targets for cardiac fibrosis: from old school to next-gen. Journal of Clinical Investigation, 2022, 132, .	8.2	53
32	Endoplasmic Reticulum Stress Effector CCAAT/Enhancerâ€binding Protein Homologous Protein (CHOP) Regulates Chronic Kidney Diseaseâ€“Induced Vascular Calcification. Journal of the American Heart Association, 2014, 3, e000949.	3.7	49
33	BET-ting on chromatin-based therapeutics for heart failure. Journal of Molecular and Cellular Cardiology, 2014, 74, 98-102.	1.9	48
34	Epigenetic regulation of cardiac fibrosis. Journal of Molecular and Cellular Cardiology, 2016, 92, 206-213.	1.9	47
35	Gold Nanoparticle-Functionalized Reverse Thermal Gel for Tissue Engineering Applications. ACS Applied Materials & Interfaces, 2019, 11, 18671-18680.	8.0	47
36	Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor. ACS Medicinal Chemistry Letters, 2020, 11, 706-712.	2.8	47

#	Article	IF	Citations
37	BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Research, 2017, 6, 1015.	1.6	47
38	Non-sirtuin histone deacetylases in the control of cardiac aging. Journal of Molecular and Cellular Cardiology, 2015, 83, 14-20.	1.9	44
39	Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 267-279.	2.5	42
40	Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation. Science Translational Medicine, 2019, 11, .	12.4	41
41	Protein kinase Câ€related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases. FEBS Letters, 2010, 584, 1103-1110.	2.8	39
42	Diet and sex modify exercise and cardiac adaptation in the mouse. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H135-H145.	3.2	35
43	The Biology and Therapeutic Implications of HDACs in the Heart. Handbook of Experimental Pharmacology, 2011, 206, 57-78.	1.8	34
44	Maturation of Pluripotent Stem Cell-Derived Cardiomyocytes Enables Modeling of Human Hypertrophic Cardiomyopathy. Stem Cell Reports, 2021, 16, 519-533.	4.8	33
45	Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. Journal of Molecular and Cellular Cardiology, 2016, 97, 106-113.	1.9	31
46	HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression. Journal of Biological Chemistry, 2019, 294, 8640-8652.	3.4	27
47	Defining decreased protein succinylation of failing human cardiac myofibrils in ischemic cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2020, 138, 304-317.	1.9	27
48	Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series). Pulmonary Circulation, 2015, 5, 63-72.	1.7	26
49	Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 140-150.	2.5	24
50	Myofibril growth during cardiac hypertrophy is regulated through dual phosphorylation and acetylation of the actin capping protein CapZ. Cellular Signalling, 2016, 28, 1015-1024.	3.6	23
51	Epigenetic therapies in heart failure. Journal of Molecular and Cellular Cardiology, 2019, 130, 197-204.	1.9	23
52	Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Cellular Signalling, 2014, 26, 2912-2920.	3.6	21
53	Epigenomic regulation of heart failure: integrating histone marks, long noncoding RNAs, and chromatin architecture. F1000Research, 2018, 7, 1713.	1.6	20
54	Histone deacetylase 6 inhibition restores leptin sensitivity and reduces obesity. Nature Metabolism, 2022, 4, 44-59.	11.9	20

#	Article	IF	Citations
55	Site-specific acetyl-mimetic modification of cardiac troponin I modulates myofilament relaxation and calcium sensitivity. Journal of Molecular and Cellular Cardiology, 2020, 139, 135-147.	1.9	19
56	A PDE3A Promoter Polymorphism Regulates cAMP-Induced Transcriptional Activity in Failing Human Myocardium. Journal of the American College of Cardiology, 2019, 73, 1173-1184.	2.8	18
57	Suppression of canonical TGF-Î² signaling enables GATA4 to interact with H3K27me3 demethylase JMJD3 to promote cardiomyogenesis. Journal of Molecular and Cellular Cardiology, 2021, 153, 44-59.	1.9	18
58	Female and male mice have differential longterm cardiorenal outcomes following a matched degree of ischemiaâ€"reperfusion acute kidney injury. Scientific Reports, 2022, 12, 643.	3.3	18
59	Acute Kidney Injury Results in Long-Term Diastolic Dysfunction That Is Prevented by Histone Deacetylase Inhibition. JACC Basic To Translational Science, 2021, 6, 119-133.	4.1	17
60	Cortical bone stem cells modify cardiac inflammation after myocardial infarction by inducing a novel macrophage phenotype. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H684-H701.	3.2	16
61	Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition. Journal of Translational Medicine, 2014, 12, 314.	4.4	15
62	Cortical bone stem cell-derived exosomesâ€™ therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H1014-H1029.	3.2	14
63	Matrix-Degrading Enzyme Expression and Aortic Fibrosis During Continuous-Flow Left Ventricular Mechanical Support. Journal of the American College of Cardiology, 2021, 78, 1782-1795.	2.8	14
64	Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2017, 112, 74-82.	1.9	12
65	HDAC6 modulates myofibril stiffness and diastolic function of the heart. Journal of Clinical Investigation, 2022, 132, .	8.2	12
66	Cardiac Remodeling During Pregnancy With Metabolic Syndrome. Circulation, 2021, 143, 699-712.	1.6	11
67	Promiscuous actions of small molecule inhibitors of the protein kinase Dâ€class IIa HDAC axis in striated muscle. FEBS Letters, 2015, 589, 1080-1088.	2.8	10
68	DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H382-H389.	3.2	10
69	Reversible lysine fatty acylation of an anchoring protein mediates adipocyte adrenergic signaling. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	10
70	A high-performance liquid chromatography assay for quantification of cardiac myosin heavy chain isoform protein expression. Analytical Biochemistry, 2011, 408, 132-135.	2.4	8
71	The ryanodine receptor stabilizer S107 ameliorates contractility of adult Rbm20 knockout rat cardiomyocytes. Physiological Reports, 2021, 9, e15011.	1.7	7
72	Regulation of extracellular matrix composition by fibroblasts during perinatal cardiac maturation. Journal of Molecular and Cellular Cardiology, 2022, 169, 84-95.	1.9	7

#	Article	IF	Citations
73	p38Î±. Circulation, 2017, 136, 562-565.	1.6	6
74	T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR. Cell Stem Cell, 2022, 29, 352-354.	11.1	4
75	ABHD5 cleaves HDAC4 to benefit the heart. Nature Metabolism, 2019, 1, 1034-1035.	11.9	3
76	A Phosphatase Anchor Weighs on the Heart. Circulation, 2020, 142, 963-966.	1.6	3
77	TNAP: a new player in cardiac fibrosis? Focus on â€œTissue-nonspecific alkaline phosphatase as a target of sFRP2 in cardiac fibroblastsâ€• American Journal of Physiology - Cell Physiology, 2015, 309, C137-C138.	4.6	2
78	Putting the Heat on Cardiac Fibrosis. JACC Basic To Translational Science, 2019, 4, 200-203.	4.1	2
79	COVID-19 and BRD4: a stormy and cardiotoxic bromo-romance. , 2022, 2, .		2
80	Arterial wall rejuvenation: the potential of targeting MMP2 to treat vascular aging. Cardiovascular Research, 2022, , .	3.8	1
81	ERRing on the Side of a Mature Heart. Circulation Research, 2020, 126, 1703-1705.	4.5	0
82	Cat-apulting Toward a Molecular Understanding of HFpEF. JACC Basic To Translational Science, 2021, 6, 673-675.	4.1	0
83	DUSP5 Functions in a Feedback Loop to Suppress TNFÎ±â€Induced ERK1/2 Phosphorylation and Inflammation in Adipocytes. FASEB Journal, 2017, 31, 794.12.	0.5	0
84	Tissue is the issue: Endomyocardial biopsies to elucidate molecular mechanisms and tailor therapy for HFpEF. Journal of Molecular and Cellular Cardiology, 2022, 169, 111-112.	1.9	0